Literature DB >> 20875873

Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML.

Birgitte S Preiss1, Olav J Bergmann, Olav J Bergman, Lone S Friis, Anne G Sørensen, Michael Frederiksen, Ole V Gadeberg, Torben Mourits-Andersen, Birthe Oestergaard, Gitte B Kerndrup.   

Abstract

During a 15-year period, 161 adult patients were diagnosed with secondary acute myeloid leukemia (s-AML) in the region of Southern Denmark. In 73 patients, the AML diagnosis was preceded by myelodysplastic syndrome (MDS-AML), in 31 patients by an antecedent hematologic disease, and in 57 patients by treatment with chemotherapy and/or irradiation (t-AML). Cytogenetic analysis was carried out in 93%, of which 61% had clonal chromosome aberrations. MDS-AML correlated to a normal karyotype (P < 0.001). t-AML correlated to abnormal clones with numerical and structural aberrations (P = 0.03), five or more unrelated aberrations (P = 0.03), marker chromosomes (P = 0.006), abnormal mitoses only (P = 0.01), female sex (P < 0.001), and -7 (P = 0.006). Centromeric breakage correlated to a complex karyotype (P = 0.01). The frequencies of aberrations in s-AML patients were compared with an age-matched group of de novo AML patients diagnosed in the same area and period. In this comparison, s-AML only correlated to -7 (P = 0.02). In 42 patients, we found that MDS patients with an abnormal karyotype were more likely to show cytogenetic evolution during progression to AML than MDS patients with a normal karyotype (P = 0.01). We conclude that population-based cytogenetic studies of adult s-AML and age- and sex-matched de novo AML show comparable distributions of chromosome abnormalities.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20875873     DOI: 10.1016/j.cancergencyto.2010.06.013

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms.

Authors:  Rashmi S Goswami; Sa A Wang; Courtney DiNardo; Zhenya Tang; Yan Li; Wenli Zuo; Shimin Hu; Shaoying Li; L Jeffrey Medeiros; Guilin Tang
Journal:  Mod Pathol       Date:  2016-04-08       Impact factor: 7.842

2.  Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.

Authors:  F V Michelis; E G Atenafu; V Gupta; D D Kim; J Kuruvilla; J H Lipton; D Loach; M D Seftel; J Uhm; N Alam; A Lambie; L McGillis; H A Messner
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

3.  Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Authors:  Prajwal Boddu; Hagop M Kantarjian; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Kapil N Bhalla; Naval Daver; Courtney D DiNardo; Christopher B Benton; Koichi Takahashi; Zeev Estrov; Sherry R Pierce; Michael Andreeff; Jorge E Cortes; Tapan M Kadia
Journal:  Blood Adv       Date:  2017-07-19

Review 4.  Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.

Authors:  Simon B Zeichner; Martha L Arellano
Journal:  Curr Treat Options Oncol       Date:  2015-08

5.  Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report.

Authors:  Masahide Yamamoto; Sayaka Suzuki; Jun-Ichi Mukae; Keisuke Tanaka; Ken Watanabe; Gaku Oshikawa; Tetsuya Fukuda; Naomi Murakami; Osamu Miura
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

6.  Analysis of hematopoietic stem cell transplant engraftment: use of loss or gain of microsatellite alleles to identify residual hematopoietic malignancy.

Authors:  Ming-Tseh Lin; Li-Hui Tseng; Katie Beierl; Shuko Harada; Michael J Hafez; James R Eshleman; Christopher D Gocke
Journal:  Diagn Mol Pathol       Date:  2011-12

7.  Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.

Authors:  Salyka Sengsayadeth; Katie S Gatwood; Ariane Boumendil; Myriam Labopin; Jürgen Finke; Arnold Ganser; Matthias Stelljes; Gerhard Ehninger; Dietrich Beelen; Dietger Niederwieser; Didier Blaise; Peter Dreger; Ghulam Mufti; Patrice Chevallier; Audrey Mailhol; Maria H Gilleece; Norbert Gorin; Jordi Esteve; Fabio Ciceri; Frederic Baron; Christoph Schmid; Sebastian Giebel; Mohamad Mohty; Bipin N Savani; Arnon Nagler
Journal:  Blood Adv       Date:  2018-08-28

8.  CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.

Authors:  Megan E McNerney; Christopher D Brown; Xiaoyue Wang; Elizabeth T Bartom; Subhradip Karmakar; Chaitanya Bandlamudi; Shan Yu; Jinkyung Ko; Barry P Sandall; Thomas Stricker; John Anastasi; Robert L Grossman; John M Cunningham; Michelle M Le Beau; Kevin P White
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

Review 9.  Prognostic Markers of Myelodysplastic Syndromes.

Authors:  Yuliya Andreevna Veryaskina; Sergei Evgenievich Titov; Igor Borisovich Kovynev; Tatiana Ivanovna Pospelova; Igor Fyodorovich Zhimulev
Journal:  Medicina (Kaunas)       Date:  2020-07-27       Impact factor: 2.430

10.  The G⁵¹⁶T CYP2B6 germline polymorphism affects the risk of acute myeloid leukemia and is associated with specific chromosomal abnormalities.

Authors:  Aggeliki Daraki; Sophia Zachaki; Theodora Koromila; Paraskevi Diamantopoulou; Gabriel E Pantelias; Constantina Sambani; Vasiliki Aleporou; Panagoula Kollia; Kalliopi N Manola
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.